NYSE
ELV

Elevance Health Inc. — Fundamental Stock Analysis and Report Card

Healthcare : Medical - Healthcare Plans

Located in Indianapolis, IN, US. Operating as a major health benefits organization, Elevance Health Inc. commits to guiding consumers, families, and communities across their entire health and wellness path. It facilitates access to vital care, assistance, and tools designed to enable healthier living for approximately 118 million individuals. The company's comprehensive offerings span medical, digital, pharmaceutical, behavioral health, clinical, and other care solutions. Founded in 1944 and based in Indianapolis, Indiana, this entity adopted its current name, Elevance Health Inc., in June 2022, having previously operated as Anthem, Inc.

Price
373.11
Low 365.38377.76 High
Percentage Change
0.07%
0.26 Price Change
Trading Volume
1.92m
1.8m Average Volume
Market Capitalization
80.92b
97.1k Employed
Growth

Revenue, earnings and profitability.

Strong revenue growth and earnings can attract investors, driving the stock price up. Profitability indicates the company's efficiency and sustainability, which impacts investor confidence. Poor performance in these areas can lead to a decrease in stock price.

Revenue TTM
200.16b
922.96 per share
Revenue Growth TTM
6.27%
Price to Sales
0.40x
Ratio TTM
Price/Sales to Growth
0.06x
Ratio TTM
Net Income TTM
4.94b
22.78 per share
Net Income Growth TTM
-7.41%
Price to Earning
16.58x
Ratio TTM
Price/Earning to Growth
n/a
Ratio TTM

Revenue History

Earnings History

Margins

Gross Margin TTM
38.95%
EBITDA Margin TTM
3.98%
Net Margin TTM
2.47%
Earnings Per Share TTM
22.78
Statements

Income & Cash Flow analysis.

An income statement shows what a company earned and spent over a period — revenue at the top, costs and expenses in between, and net income at the bottom. A cash flow statement tracks the actual cash moving in and out, across operations, investing, and financing. Read together, they show whether reported earnings are backed by real cash.

Elevance Health Inc.
Select Period:
Q2 2026
Total ($)
Q2 2026
Margin (%)
Revenue
50.5b
+698.0m
+1.4%
Gross Income
45.0b
+31.9b
+244.2%
89%
+62.9pp
+239.4%
EBITDA
2.1b
-910.0m
-30.2%
4%
-1.9pp
-31.2%
Operating Income
2.1b
-570.0m
-21.6%
4%
-1.2pp
-22.7%
Net Income
1.5b
-280.0m
-16.1%
3%
-0.6pp
-17.2%
Earnings Per Share
6.71
-1.0
-13.1%
Operating Cash Flow
1.9b
-141.0m
-6.9%
4%
-0.3pp
-8.2%
Free Cash Flow
1.6b
-161.0m
-9.0%
3%
-0.4pp
-10.3%
Research & Development
n/a
n/a
n/a
n/a
n/a
n/a